Australia TGA ARTG recordEVER Pharma - Basic insulin pen, replaceable-cartridge
Australia TGA ARTG Registered Device · Interpharma Pty Ltd · EVER Neuro Pharma GmbH · Class IIa · Started January 15, 2018
Good Name: EVER Pharma - Basic insulin pen, replaceable-cartridge
- Risk Class
- Class IIa
- Product Type
- Single Device Product
- ARTG Category
- General
- Start Date
- January 15, 2018
- Effective Date
- January 15, 2018
- Country
- Austria
- Address
- Oberburgau 3, Unterach, Osterreich, 4866
The intended use of the Apomine D-mine Pen is to deliver Apomorphine subcutaneously in patients with Parkinsons's disease on a daily basis. The intermittent administration via Pen application allows the rescue therapy with stimulation of striatal dopamine receptors which matches the physiological situation of the striatum in the brain.
Access comprehensive regulatory information for EVER Pharma - Basic insulin pen, replaceable-cartridge in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIa is sponsored by Interpharma Pty Ltd, manufactured by EVER Neuro Pharma GmbH in Austria. The device registration started on January 15, 2018.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.